{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T19:05:02Z","timestamp":1774897502998,"version":"3.50.1"},"reference-count":82,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2018,5,23]],"date-time":"2018-05-23T00:00:00Z","timestamp":1527033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The introduction of novel frontline agents in multiple myeloma (MM), like immunomodulatory drugs and proteasome inhibitors, has improved the overall survival of patients. Yet, MM is still not curable, and drug resistance (DR) remains the main challenge. To improve the understanding of DR in MM, we established a resistant cell line (MOLP8\/R). The exploration of DR mechanisms yielded an overexpression of HIF1\u03b1, due to impaired proteasome activity of MOLP8\/R. We show that MOLP8\/R, like other tumor cells, overexpressing HIF1\u03b1, have an increased resistance to the immune system. By exploring the main target genes regulated by HIF1\u03b1, we could not show an overexpression of these targets in MOLP8\/R. We, however, show that MOLP8\/R cells display a very high overexpression of LCP1 gene (l-Plastin) controlled by HIF1\u03b1, and that this overexpression also exists in MM patient samples. The l-Plastin activity is controlled by its phosphorylation in Ser5. We further show that the inhibition of l-Plastin phosphorylation restores the sensitivity of MOLP8\/R to immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). Our results reveal a new target gene of DR, controlled by HIF1\u03b1.<\/jats:p>","DOI":"10.3390\/ijms19061551","type":"journal-article","created":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T02:55:43Z","timestamp":1527130543000},"page":"1551","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Inhibition of HIF1\u03b1-Dependent Upregulation of Phospho-l-Plastin Resensitizes Multiple Myeloma Cells to Frontline Therapy"],"prefix":"10.3390","volume":"19","author":[{"given":"Manon","family":"Bosseler","sequence":"first","affiliation":[{"name":"Laboratory of Experimental Cancer Research, Luxembourg Institute of Health (LIH), L-1526 Luxembourg City, Luxembourg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Marani","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Cancer Research, Luxembourg Institute of Health (LIH), L-1526 Luxembourg City, Luxembourg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelina","family":"Broukou","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Cancer Research, Luxembourg Institute of Health (LIH), L-1526 Luxembourg City, Luxembourg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amandine","family":"Lequeux","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Cancer Research, Luxembourg Institute of Health (LIH), L-1526 Luxembourg City, Luxembourg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony","family":"Kaoma","sequence":"additional","affiliation":[{"name":"Bioinformatics and Modelling, Luxembourg Institute of Health (LIH), L-1526 Luxembourg City, Luxembourg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Schlesser","sequence":"additional","affiliation":[{"name":"Laboratory of Hematology, Centre Hospitalier de Luxembourg (CHL), L-1526 Luxembourg City, Luxembourg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Hugues","family":"Fran\u00e7ois","sequence":"additional","affiliation":[{"name":"Laboratory of Hematology, Centre Hospitalier de Luxembourg (CHL), L-1526 Luxembourg City, Luxembourg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Palissot","sequence":"additional","affiliation":[{"name":"Laboratory of Oncolytic-Virus-Immuno-Therapeutics, Luxembourg Institute of Health (LIH), L-1526 Luxembourg City, Luxembourg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy J.","family":"Berchem","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Cancer Research, Luxembourg Institute of Health (LIH), L-1526 Luxembourg City, Luxembourg"},{"name":"Laboratory of Hematology, Centre Hospitalier de Luxembourg (CHL), L-1526 Luxembourg City, Luxembourg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nass\u00e9ra","family":"Aouali","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Cancer Research, Luxembourg Institute of Health (LIH), L-1526 Luxembourg City, Luxembourg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bassam","family":"Janji","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Cancer Research, Luxembourg Institute of Health (LIH), L-1526 Luxembourg City, Luxembourg"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2018,5,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","article-title":"Multiple myeloma: Diagnosis and treatment","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Mayo Clin. Proc."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/ajh.24236","article-title":"Myeloma today: Disease definitions and treatment advances","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.18632\/oncotarget.6658","article-title":"Novel strategies to target the ubiquitin proteasome system in multiple myeloma","volume":"7","author":"Lub","year":"2016","journal-title":"Oncotarget"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"341430","DOI":"10.1155\/2015\/341430","article-title":"Mechanisms of drug resistance in relapse and refractory multiple myeloma","volume":"2015","author":"Yang","year":"2015","journal-title":"BioMed Res. Int."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/205873920601900107","article-title":"c-MYC deregulation is involved in melphalan resistance of multiple myeloma: Role of PDGF-BB","volume":"19","author":"Greco","year":"2006","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1038\/bcj.2013.1","article-title":"MEK inhibitors as a chemotherapeutic intervention in multiple myeloma","volume":"3","author":"Gerondakis","year":"2013","journal-title":"Blood Cancer J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1002\/stem.2199","article-title":"Myeloma propagating cells, drug resistance and relapse","volume":"33","author":"Karadimitris","year":"2015","journal-title":"Stem Cells"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"44541","DOI":"10.1038\/srep44541","article-title":"Identification of the metabolic alterations associated with the multidrug resistant phenotype in cancer and their intercellular transfer mediated by extracellular vesicles","volume":"7","author":"Mleczko","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3389\/fphar.2013.00028","article-title":"Mechanisms and insights into drug resistance in cancer","volume":"4","author":"Zahreddine","year":"2013","journal-title":"Front. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.18632\/oncotarget.1497","article-title":"Drug resistance in multiple myeloma: Latest findings and new concepts on molecular mechanisms","volume":"4","author":"Abdi","year":"2013","journal-title":"Oncotarget"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1182\/blood.V74.3.913.913","article-title":"P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD","volume":"74","author":"Epstein","year":"1989","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev.bi.62.070193.002125","article-title":"Biochemistry of multidrug resistance mediated by the multidrug transporter","volume":"62","author":"Gottesman","year":"1993","journal-title":"Annu. Rev. Biochem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2174\/138161282005140214165212","article-title":"ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development","volume":"20","author":"Choi","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev-pathol-011110-130249","article-title":"Pathogenesis of myeloma","volume":"6","author":"Anderson","year":"2011","journal-title":"Annu. Rev. Pathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2012-01-379024","article-title":"Myeloma as a model for the process of metastasis: Implications for therapy","volume":"120","author":"Ghobrial","year":"2012","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1182\/blood-2014-11-568881","article-title":"Pathogenesis beyond the cancer clone(s) in multiple myeloma","volume":"125","author":"Bianchi","year":"2015","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0006-3495(01)75732-3","article-title":"Modeling pO(2) distributions in the bone marrow hematopoietic compartment. I. Krogh\u2019s model","volume":"81","author":"Chow","year":"2001","journal-title":"Biophys. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"232896","DOI":"10.1155\/2013\/232896","article-title":"Effects of severe hypoxia on bone marrow mesenchymal stem cells differentiation potential","volume":"2013","author":"Cicione","year":"2013","journal-title":"Stem Cells Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nrc1187","article-title":"Targeting HIF-1 for cancer therapy","volume":"3","author":"Semenza","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.apsb.2015.05.007","article-title":"HIF-1alpha pathway: Role, regulation and intervention for cancer therapy","volume":"5","author":"Masoud","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5680","DOI":"10.1073\/pnas.88.13.5680","article-title":"Hypoxia-inducible nuclear factors bind to an enhancer element located 3\u2019 to the human erythropoietin gene","volume":"88","author":"Semenza","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","first-page":"706","article-title":"Hypoxia inducible factor-1\u03b1 and multiple myeloma","volume":"4","author":"Bhaskar","year":"2016","journal-title":"Int. J. Adv. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/onc.2013.121","article-title":"Tumor stroma: A complexity dictated by the hypoxic tumor microenvironment","volume":"33","author":"Casazza","year":"2014","journal-title":"Oncogene"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10555-007-9055-1","article-title":"Hypoxia in cancer: Significance and impact on clinical outcome","volume":"26","author":"Vaupel","year":"2007","journal-title":"Cancer Metast. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.tibs.2012.06.004","article-title":"Passing the baton: The HIF switch","volume":"37","author":"Koh","year":"2012","journal-title":"Trends Biochem. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5782","DOI":"10.1182\/blood-2011-09-380410","article-title":"Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features","volume":"119","author":"Azab","year":"2012","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1158\/1541-7786.MCR-10-0139","article-title":"Mechanisms of motility in metastasizing cells","volume":"8","author":"Yilmaz","year":"2010","journal-title":"Mol. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1096\/fj.15-276311","article-title":"l-Plastin Ser5 phosphorylation in breast cancer cells and in vitro is mediated by RSK downstream of the ERK\/MAPK pathway","volume":"30","author":"Lommel","year":"2016","journal-title":"FASEB J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1242\/jcs.02874","article-title":"Phosphorylation on Ser5 increases the F-actin-binding activity of l-Plastin and promotes its targeting to sites of actin assembly in cells","volume":"119","author":"Janji","year":"2006","journal-title":"J. Cell Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood-2007-11-120576","article-title":"Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1","volume":"111","author":"Shin","year":"2008","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.mvr.2008.08.003","article-title":"The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions","volume":"77","author":"Lu","year":"2009","journal-title":"Microvasc. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.yexcr.2014.09.018","article-title":"HIF-1alpha inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment","volume":"328","author":"Borsi","year":"2014","journal-title":"Exp. Cell Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/jcmm.12279","article-title":"Proteasome inhibitors\u2014Molecular basis and current perspectives in multiple myeloma","volume":"18","author":"Kubiczkova","year":"2014","journal-title":"J. Cell. Mol. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"6820","DOI":"10.1158\/0008-5472.CAN-14-0303","article-title":"ITPR1 protects renal cancer cells against natural killer cells by inducing autophagy","volume":"74","author":"Messai","year":"2014","journal-title":"Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"24349","DOI":"10.1074\/jbc.274.34.24349","article-title":"Immune complex-induced integrin activation and l-Plastin phosphorylation require protein kinase A","volume":"274","author":"Wang","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1111\/j.1582-4934.2009.00918.x","article-title":"The actin filament cross-linker l-Plastin confers resistance to TNF-alpha in MCF-7 breast cancer cells in a phosphorylation-dependent manner","volume":"14","author":"Janji","year":"2010","journal-title":"J. Cell. Mol. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1527-3466.2006.00261.x","article-title":"The many faces of H89: A review","volume":"24","author":"Lochner","year":"2006","journal-title":"Cardiovasc. Drug Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1586\/17474086.2014.858595","article-title":"Future agents and treatment directions in multiple myeloma","volume":"7","author":"Ocio","year":"2014","journal-title":"Expert Rev. Hematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1038\/bcj.2013.38","article-title":"Pomalidomide: The new immunomodulatory agent for the treatment of multiple myeloma","volume":"3","author":"Swaika","year":"2013","journal-title":"Blood Cancer J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/leu.2017.329","article-title":"Management of relapsed and refractory multiple myeloma: Novel agents, antibodies, immunotherapies and beyond","volume":"32","author":"Chim","year":"2018","journal-title":"Leukemia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: Report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13045-016-0282-1","article-title":"Novel agents in the treatment of multiple myeloma: A review about the future","volume":"9","author":"Naymagon","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/17474086.2018.1456331","article-title":"Anti-CD38 and anti-SLAMF7: The future of myeloma immunotherapy","volume":"11","author":"Zamagni","year":"2018","journal-title":"Expert Rev. Hematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/imr.12233","article-title":"Targeting the bone marrow microenvironment in multiple myeloma","volume":"263","author":"Kawano","year":"2015","journal-title":"Immunol. Rev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-016-0284-z","article-title":"Elotuzumab for the treatment of multiple myeloma","volume":"9","author":"Wang","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-016-0283-0","article-title":"Daratumumab: A first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma","volume":"9","author":"Sanchez","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/1744666X.2016.1209112","article-title":"The role of SLAMF7 in multiple myeloma: Impact on therapy","volume":"13","author":"Boudreault","year":"2017","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/onc.2009.441","article-title":"Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics","volume":"29","author":"Semenza","year":"2010","journal-title":"Oncogene"},{"key":"ref_56","first-page":"253","article-title":"Progress toward overcoming hypoxia-induced resistance to solid tumor therapy","volume":"7","author":"Karakashev","year":"2015","journal-title":"Cancer Manag. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.critrevonc.2015.07.003","article-title":"An update on molecular biology and drug resistance mechanisms of multiple myeloma","volume":"96","author":"Mutlu","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3892\/ijo.2016.3516","article-title":"Multiple myeloma and persistence of drug resistance in the age of novel drugs (Review)","volume":"49","author":"Krishnan","year":"2016","journal-title":"Int. J. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Begicevic, R.R., and Falasca, M. (2017). ABC Transporters in cancer stem cells: Beyond chemoresistance. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18112362"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40265-017-0841-y","article-title":"Current and new therapeutic strategies for relapsed and refractory multiple myeloma: An update","volume":"78","author":"Nijhof","year":"2018","journal-title":"Drugs"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/s41598-018-19325-x","article-title":"Targeted inhibitors of P-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor cells","volume":"8","author":"Nanayakkara","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/bjh.14992","article-title":"Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma","volume":"180","author":"Cohen","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/bloodadvances.2017013334","article-title":"Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma","volume":"2","author":"Merz","year":"2018","journal-title":"Blood Adv."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3390\/cancers6031769","article-title":"Drug resistance in cancer: An overview","volume":"6","author":"Housman","year":"2014","journal-title":"Cancers"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/leu.2017.212","article-title":"Carfilzomib resistance due to ABCB1\/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma","volume":"32","author":"Besse","year":"2018","journal-title":"Leukemia"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: A report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e365","DOI":"10.1038\/bcj.2015.92","article-title":"Interpretation of cytogenetic results in multiple myeloma for clinical practice","volume":"5","author":"Rajan","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/ejh.12255","article-title":"Immunoglobulin D myeloma: Clinical features and outcome in the era of novel agents","volume":"92","author":"Zagouri","year":"2014","journal-title":"Eur. J. Haematol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"6230","DOI":"10.1158\/0008-5472.CAN-12-1345","article-title":"Tumor cells upregulate normoxic HIF-1alpha in response to doxorubicin","volume":"73","author":"Cao","year":"2013","journal-title":"Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3892\/or.2014.3181","article-title":"Involvement of HIF-1alpha activation in the doxorubicin resistance of human osteosarcoma cells","volume":"32","author":"Roncuzzi","year":"2014","journal-title":"Oncol. Rep."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e26494","DOI":"10.4161\/onci.26494","article-title":"Trial Watch: Lenalidomide-based immunochemotherapy","volume":"2","author":"Semeraro","year":"2013","journal-title":"Oncoimmunology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1182\/blood-2014-02-557819","article-title":"Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma","volume":"124","author":"Zhu","year":"2014","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1478-811X-11-42","article-title":"Hypoxia-inducible factor (HIF) network: Insights from mathematical models","volume":"11","author":"Cavadas","year":"2013","journal-title":"Cell Commun. Signal."},{"key":"ref_74","first-page":"1454","article-title":"A dynamic model of the hypoxia-inducible factor 1alpha (HIF-1\u03b1) network","volume":"126","author":"Nguyen","year":"2013","journal-title":"J. Cell Sci."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"C569","DOI":"10.1152\/ajpcell.00207.2015","article-title":"Hypoxia: A key player in antitumor immune response. A review in the theme: Cellular responses to hypoxia","volume":"309","author":"Noman","year":"2015","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Sarkar, S., Germeraad, W.T., Rouschop, K.M., Steeghs, E.M., van Gelder, M., Bos, G.M., and Wieten, L. (2013). Hypoxia induced impairment of NK cell cytotoxicity against multiple myeloma can be overcome by IL-2 activation of the NK cells. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0064835"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2147\/HP.S93413","article-title":"The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy","volume":"3","author":"Muz","year":"2015","journal-title":"Hypoxia"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1002\/eji.201041366","article-title":"l-Plastin phosphorylation: A novel target for the immunosuppressive drug dexamethasone in primary human T cells","volume":"41","author":"Wabnitz","year":"2011","journal-title":"Eur. J. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"40662","DOI":"10.1038\/srep40662","article-title":"The calcium-dependent switch helix of l-Plastin regulates actin bundling","volume":"7","author":"Ishida","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.leukres.2003.12.008","article-title":"Induction of CD28 on the new myeloma cell line MOLP-8 with t(11;14)(q13;q32) expressing delta\/lambda type immunoglobulin","volume":"28","author":"Matsuo","year":"2004","journal-title":"Leuk. Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nm0895-822","article-title":"Tumour suppression by the human von Hippel-Lindau gene product","volume":"1","author":"Iliopoulos","year":"1995","journal-title":"Nat. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/6\/1551\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:05:33Z","timestamp":1760195133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/6\/1551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,23]]},"references-count":82,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,6]]}},"alternative-id":["ijms19061551"],"URL":"https:\/\/doi.org\/10.3390\/ijms19061551","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,23]]}}}